N/A
N=110
Relaxing Environment to Lower Anxiety During Onabotulinum Toxin Chemodenervation of the Bladder
Anxiety · Pain · Burnout, Professional
Bottom Line
View on ClinicalTrials.gov: NCT06319898 ↗Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Mean Change in Visual Analog Scale (VAS) Anxiety Scores — -13.8; -4.7 mm
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Lavender aromatherapy sticker (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Aug 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change in Visual Analog Scale (VAS) Anxiety Scores |
-13.8; -4.7 | — |
| SECONDARY Mean Change in Visual Analog Scale (VAS) Pain During the Chemodenervation Procedure |
0.0; 3.7 | — |
| SECONDARY Procedure Staff Burnout Scores - Burnout Battery Visual Analog Scale for Healthcare Worker Burnout |
-1.73; 1.31 | — |
| SECONDARY Patient Satisfaction With Their Procedure Experience Scores |
91.4; 89.3 | — |
Summary
Chemodenervation of the bladder with onabotulinum toxin A is an effective treatment option for patients with refractory urgency urinary incontinence (UUI). It is often performed as an office-based procedure under local anesthesia. Alternatively, it can be performed in the operating room under general anesthesia. The ability to receive intra-detrusor chemodenervation in the office allows patients to avoid the risks associated with general anesthesia and is significantly more cost effective. The procedure, however, is painful and can be anxiety provoking for patients; especially given that patients typically return every six to nine months for repeat injections. Relaxation and distraction techniques are one way to ease patients' anxiety before an office-based procedure. While we do not know exactly how anxiety provoking office bladder chemodenervation is for patients, we do know that anxiety disorders are highly prevalent in women with overactive bladder as a population.
The purpose of this study is to investigate whether women with Urge urinary incontinence (UUI) who receive office intra-detrusor chemodenervation injections performed in a relaxing environment of lavender aromatherapy, calming music, dim lighting, and modest positioning (Relaxing Environment Package) will have decreased anxiety and pain as well as increased post-procedure satisfaction compared to patients who receive chemodenervation in a typical office environment. Also investigate whether exposure to the relaxing environment impacts the well-being of staff involved in these procedures. This study design is a randomized control trial. Women scheduled for office intra-detrusor chemodenervation at Atrium Health women's Care Urogynecology & Pelvic Surgery - Mercy clinic will be invited to participate. Participants will be randomized to the relaxing environment package or the placebo group after informed consent is obtained and immediately before undergoing intra-detrusor chemodenervation. The participants will complete the pre-procedure visual analog scale (VAS) for anxiety and a VAS for pain at baseline.
Eligibility Criteria
Inclusion Criteria
- Non-pregnant females
- Age 18 years and older
- English as a primary language
- Scheduled for office intra-detrusor chemodenervation for diagnosis of Over-Active Bladder (OAB)/ Urinary Urgency (UU)/ Urged Urinary Incontinence (UUI)
- Baseline visual analog scale for anxiety ≥12mm
Exclusion Criteria
- Allergy to lavender oil
- Contraindication to intra-detrusor chemodenervation (active Urinary Tract Infection)
Data sourced from ClinicalTrials.gov (NCT06319898). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.